A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

India has joined the Global Antibiotic Research and Development Partnership (GARDP)-led NeoSep1 clinical trial, a landmark international study evaluating new antibiotic treatments for newborns with drug-resistant sepsis.

Sepsis is the second leading cause of neonatal mortality in India after prematurity and low birth weight, accounting for an estimated 30–40 per cent of all newborn deaths.

The NeoSep1 trial began in India with the first baby enrolled at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry, followed by Pt. B.D. Sharma PGIMS in Rohtak. Lokmanya Tilak Municipal Medical College and General Hospital in Mumbai is also expected to begin enrolling newborns soon.

"Every day doctors face the heartbreaking reality of losing babies to sepsis due to lack of safe and effective treatments," said Dr Nishad Plakkal, Principal Investigator of the NeoSep1 trial in India and Associate Dean (Research) and Professor and Head of the Department of Neonatology at JIPMER.

"Having the right antibiotics at the right dose can tip the balance between life and death. This trial offers hope to change that," Plakkal added.

"The trial will give neonatologists new tools, and give babies with sepsis a fighting chance at life," said Sally Ellis, who leads GARDP's Children's Antibiotics Program.

Why Newborns Are At Greater Risk

Also read:US Woman Nearly Died After Brushing Off Sepsis Symptoms As Flu

According to Ellis, newborns are particularly vulnerable to life-threatening sepsis because of their underdeveloped immune systems.

The growing burden of antibiotic resistance in low- and middle-income countries (LMICs) has further worsened the problem by reducing the effectiveness of standard treatments. Studies have reported extremely high resistance to the combination of ampicillin and gentamicin, the antibiotic regimen currently recommended by the World Health Organization for the initial treatment of neonatal sepsis.

"Today, we stand at a tipping point. The antibiotics for newborns that we have relied on for decades are failing against resistant infections in many hospital settings," Ellis said.

What Is The NeoSep1 Trial?

Read More: Andhra Pradesh To Launch Rare Disease Policy, Expand Universal Newborn Screening

An estimated 3 million newborns develop sepsis every year. The condition occurs when the body's response to an infection triggers widespread inflammation, potentially leading to tissue damage, organ failure, and death. More than 90% of neonatal sepsis deaths occur in low- and middle-income countries.

The NeoSep1 trial aims to identify safe and effective antibiotic regimens that can reduce deaths caused by drug-resistant neonatal sepsis.

The first phase of the study, conducted in South Africa and Kenya in 2023, validated the appropriate doses of fosfomycin and flomoxef when used in combination with other antibiotics in newborns.

The second phase is using a Personalised Randomised Controlled Trial (PRACTical) design to evaluate and rank multiple antibiotic regimens for newborns with sepsis. The approach is expected to help clinicians choose the most effective treatments based on local patterns of antibiotic resistance while also informing future national and international treatment guidelines.

The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028.

Along with India, newborns have already been enrolled in Ghana, Kenya, and South Africa. Hospitals in Vietnam, Pakistan, Malaysia, Bangladesh, and Uganda are also expected to join the study.

Warning Signs of Sepsis

Sepsis is a life-threatening reaction to an infection that harms the immune system, tissues, and organs. It can lead to organ failure or death if not treated urgently, according to the Cleveland Clinic.

According to Sepsis Alliance, the acronym TIME can help people recognize potential warning signs of sepsis and seek urgent medical care.

T — Temperature: Body temperature is unusually high or low.

I — Infection: Signs or symptoms of an infection are present.

M — Mental Decline: Confusion, excessive sleepiness, or difficulty waking up.

E — Extremely Ill: Severe pain, extreme discomfort, or shortness of breath.

The highly pathogenic H5N1 bird flu virus has now spread to a second Australian state. Less than a week after it was first identified in two seabirds in Western Australia, authorities have confirmed another case in South Australia.

For the general public, the health risk remains low. Experts say people who don't regularly handle infected birds or animals are unlikely to contract the virus. However, Australia's poultry industry is treating the situation with extreme caution.

If the virus were to reach commercial poultry farms, the consequences could be severe. Millions of chickens and other birds could either die from the disease or be culled to stop it from spreading. Such an outbreak could also trigger export restrictions on Australian poultry products and leave farmers facing massive cleanup and recovery costs, even with government assistance.

So far, there is no evidence that H5N1 has entered any commercial poultry farms or Australia's native wild bird populations. The confirmed cases have been limited to wild seabirds.

Even so, poultry producers across the country—particularly in Western Australia and South Australia—are already tightening biosecurity measures to reduce the risk of the virus reaching their flocks.

Also Read: New Oral GLP-1 Pill Delivers Major Weight Loss In Just 36 Weeks

Australia's largest poultry producer, Inghams, has restricted access to its Western Australian farms, allowing only essential personnel to enter. The company has also requested permission from the federal government's Chief Veterinary Officer to temporarily move its free-range birds indoors. The aim is to reduce any contact between domestic poultry and wild birds, which are considered the most likely source of infection.

These additional precautions build on the strict biosecurity rules already followed by the poultry industry. Farm visits are kept to a minimum, employees are generally prohibited from keeping backyard chickens or other birds at home, and workers are discouraged from moving between different poultry facilities within a short period. Many farms also require staff to shower before entering, change into company-issued clothing, and follow rigorous hygiene procedures. Measures to keep wild birds away and control rodents and insects are also a standard part of farm management.

The H5N1 strain is particularly deadly for chickens, as well as turkeys and quail. Ducks can also become infected, but they present a different challenge because they may carry and spread the virus without showing obvious signs of illness, making them especially difficult to monitor.

Why Australia Had Remained Bird Flu-Free

Until now, Australia was the only continent where the H5N1 strain, the highly contagious strain of H5 bird flu, had not been detected. Although the virus has circulated across Asia since the 1990s and reached Antarctica in 2024, Australia had remained unaffected.

According to Dr Michelle Wille, ARC Future Fellow at the University of Melbourne, Australia's unique bird migration patterns likely delayed the virus's arrival.

"There are no duck species which routinely migrate between Australia and Asia, nor are there ducks that migrate through Antarctica," Wille wrote in The Conversation.

However, evidence suggests other seabirds—including gulls, skuas and giant petrels—may have helped carry the virus over long distances across Antarctica and subantarctic regions, eventually bringing it closer to Australia, he said.

As per the latest update, Australian scientists believe that the H5 bird flu strain killed more than 13,000 elephant seal pups after infecting a breeding colony on the remote Heard and McDonald Islands, one of Australia's external territories in the sub-Antarctic.

American supermodel Bella Hadid has opened up about the mental toll of living with Lyme disease, a chronic illness she has battled for years.

Bella Hadid was diagnosed with Lyme disease in 2013 and has endured an ongoing battle with physical pain, extreme fatigue, brain fog, and associated depression.

In a series of Instagram Stories, the 29-year-old model shared about the daily hardships and emotional toll of recurring health flare-ups despite trying various treatment protocols.

The supermodel said it is "intimidating" to explain her symptoms of pain, exhaustion, fatigue, anxiety, brain fog, infections and trauma, and how they lead "to severe isolation and depression, especially over long periods of time," People.com reported.

"Especially when you try anything you can," she said, adding that she has read books and personal stories to better understand her symptoms, yet still experiences setbacks.

Bella Hadid On Lyme Disease Flare Ups

"You demand answers that no one can find. You fight. You finally have a few good days. You think you've found the right protocol, the right routine, the right treatment... and then a flare-up comes back and all of a sudden nothing feels certain again."

Hadid said flare-ups of the chronic illness often force her to cancel plans.

"You wake up with anxiety already living in your body," Hadid wrote.

"Physical pain before your feet even touch the floor....And somehow, still have to find the strength to move through another day in a body and mind that are completely exhausted."

Bella Hadid's Hope In God

The model said she has learned to mask her feelings.

"Sometimes it feels like unless you've lived something like this, or loved someone who has, it's impossible to fully understand."

She also reminded followers facing similar struggles that "there is light, even if you can't see it today... There is hope," before sharing a message she often tells herself during difficult times.

"As so many have said..I have to remind myself that healing isn't linear...I believe God puts before us, somehow, only what we are capable of carrying, even when we don't understand why at the time," she wrote, saying there's a "deeper purpose to all things in life."

Hadid acknowledged that although it is hard, she believes "every hardship leaves us with a lesson, a deeper compassion, or a strength we never knew we had."

What Is Lyme Disease?

According to the US Centers for Disease Control and Prevention (CDC), Lyme disease is a bacterial infection spread to people through the bite of infected blacklegged ticks.

Every year, an estimated 31 million people in the United States are bitten by a tick.

Lyme disease is the most common tick-borne disease in the United States, with an estimated 476,000 patients treated for Lyme each year.

Typical symptoms include:

• Fever
• Headache
• Fatigue
• A characteristic skin rash called erythema migrans.

How to Prevent

The best defense against Lyme disease is to prevent tick bites. This will reduce your risk of other tickborne diseases as well.

What to do after a tick bite:

• Remove attached ticks as soon as possible.
• Depending on the type of tick and how long it was attached, antibiotic prophylaxis might help to prevent Lyme disease.
• Call your doctor if you develop fever, rash, or other symptoms.